Abstract:Importance: Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis. Objective: To determine the prevalence of neurological and neuropsychiatric symptoms reported 12 weeks (3 months) or more after acute COVID-19 onset in adults. Data sources: A systematic search of PubMed, EMBASE, Web of Science, Google Scholar and Scopus was conducted for studies published between January 1st, 2020 and August 1st, 2021. The systematic review was guided by Preferred Reporting Items for Systematic Review and Meta-Analyses. Study selection: Studies were included if the length of follow-up satisfied the National Institute for Healthcare Excellence (NICE) definition of post-COVID-19 syndrome (symptoms that develop or persist ≥3 months after the onset of COVID-19). Additional criteria included the reporting of neurological or neuropsychiatric symptoms in individuals with COVID-19. Data extraction and synthesis: Two authors independently extracted data on patient characteristics, hospital and/or ICU admission, acute-phase COVID-19 symptoms, length of follow-up, and neurological and neuropsychiatric symptoms. Main outcome(s) and measure(s): The primary outcome was the prevalence of neurological and neuropsychiatric symptoms reported ≥3 months post onset of COVID-19. We also compared post-COVID-19 syndrome in hospitalised vs. non-hospitalised patients, with vs. without ICU admission during the acute phase of infection, and with mid-term (3 to 6 months) and long-term (>6 months) follow-up. Results: Of 1458 articles, 19 studies, encompassing a total of 11,324 patients, were analysed. Overall prevalence for neurological post-COVID-19 symptoms were: fatigue (37%, 95% CI: 24%-50%), brain fog (32%, 9%-55%), memory issues (27%, 18%-36%), attention disorder (22%, 10%-34%), myalgia (18%, 4%-32%), anosmia (12%, 7%-17%), dysgeusia (11%, 4%-17%) and headache (10%, 1%-21%). Neuropsychiatric conditions included sleep disturbances (31%, 18%-43%), anxiety (23%, 13%-33%) and depression (12%, 7%-21%). Neuropsychiatric symptoms substantially increased in prevalence between mid- and long-term follow-up. Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced frequency of anosmia, anxiety, depression, dysgeusia, fatigue, headache, myalgia, and sleep disturbance at three (or more) months post-infection. Conversely, hospital admission was associated with higher frequency of memory issues (OR: 1.9, 95% CI: 1.4-2.3). Cohorts with >20% of patients admitted to the ICU during acute COVID-19 experienced higher prevalence of fatigue, anxiety, depression, and sleep disturbances than cohorts with <20% of ICU admission. Conclusions and relevance: Fatigue, cognitive dysfunction (brain fog, memory issues, attention disorder) and sleep disturbances appear to be key features of post-COVID-19 syndrome. Psychiatric manifestations (sleep disturbances, anxiety, and depression) are common and increase significantly in prevalence over time. Randomised controlled trials are necessary to develop intervention strategy to reduce disease burden.

Neuropsychological functioning of pediatric patients with long COVID

Neuropsychology practice guidance for the neuropsychiatric aspects of Long COVID

Mental health among children with long COVID during the COVID-19 pandemic

Neurocognitive and Neuropsychiatric Sequelae in Long COVID-19 Infection

Impact on the nervous system of long COVID-19 infection in children

1136 Sleep Disorders in Children and Adolescents with Long COVID

Long COVID neuropsychological follow-up: Is cognitive rehabilitation relevant?

Characterizing Long COVID in Children and Adolescents

Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis

Differences in cognitive and academic performance during the COVID-19 pandemic in child psychiatric outpatients.

Assessing Neuropsychiatric Symptoms in Long COVID: A Retrospective Cohort Study from a South Texas Long COVID Clinic

Longitudinal analysis and treatment of neuropsychiatric symptoms in post-acute sequelae of COVID-19

Long COVID in Children and Adolescents: A Critical Review

Neurological involvement among non-hospitalized adolescents and young adults 6 months after acute COVID-19

Autonomic cardiac function in children and adolescents with long COVID: a case-controlled study

Pediatric Long COVID Subphenotypes: An EHR-based study from the RECOVER program

Prevalence and Risk Factor for Long COVID in Children and Adolescents: A Meta-Analysis and Systematic Review

Post COVID-19 conditions in an Australian pediatric cohort, 3 months following a Delta outbreak

Brain and cognitive changes in patients with long COVID compared with infection-recovered control subjects

Neuropsychiatric Aspects of Long COVID: A Comprehensive Review

Clinical and diagnostic features of long-COVID patients presenting with neurologic symptoms in Chicago